TTIL Trial on Alzheimer’s Aggression and Agitation Treatment Now Fully Enrolled

TTIL Trial on Alzheimer’s Aggression and Agitation Treatment Now Fully Enrolled
Transition TherapeuticsThe Irish subsidiary of biopharmaceutical company Transition Therapeutics Inc. has finished patient enrollment for its phase 2 clinical study to assess a novel therapy for mild, moderate and severe Alzheimer's disease
Subscribe or to access all post and page content.